CPTX
Live / Allowed — Notice of allowance issued (as of 01 Sept 2026)
What this means for you
Approved and waiting on proof of use. It will register unless the applicant drops it, and its 23 Aug 2024 filing date already counts against anyone who files later.
Record
- Serial number
- 98714397
- Mark type
- Word mark
- Filed
- 23 Aug 2024
- Published for opposition
- 06 Jan 2026
- Attorney of record
- CATHERINE PARRISH LAKE
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations, namely, DNA, synthetic DNA and single-strand DNA for use in the fields of gene therapy, gene editing, cell therapy, cancer therapy, virus production, DNA-vaccination, gene transfer, immunotherapy, and antivirals; Drug delivery agents in the form of synthetic DNA nanostructures that facilitate the delivery of pharmaceutical preparations and therapeutic agents; Medicines comprised of DNA for gene therapy, gene editing, cell therapy, cancer therapy, virus production, DNA-vaccination, gene transfer, immunotherapy, and antivirals; Medicine delivery agents in the form of synthetic DNA nanostructures that facilitate the delivery of pharmaceutical preparations and therapeutic agents; Diagnostic preparations comprising nucleotide sequences for medical and veterinary purposes; none of the foregoing goods are used for medical coding and billing purposes
- Class 042 — Scientific and technological services: Scientific and technological services, namely scientific research and analysis in the field of DNA; biochemical and biotechnological services, namely research and development of custom-specific DNA; research services in the field of DNA, namely, analysis for scientific research purposes and repair technology, mutation and sequencing; biochemical and biotechnological services, namely protein design and development; testing of new products for third parties; scientific DNA screening for scientific research purposes for third parties; protein screening for scientific research purposes for third parties; industrial DNA screening to ensure biopharmaceutical purity and to detect and identify pathogens for third parties for the purposes of scientific and biotechnological research and development; industrial protein screening to ensure biopharmaceutical purity and to detect and identify pathogens for third parties for the purposes of scientific and biotechnological research and development; none of the foregoing services are used for medical coding and billing purposes
- Class 044 — Medical, beauty and agricultural services: Medical and pharmaceutical services in the field of DNA, namely, medical analysis of DNA for the diagnosis and treatment of persons, DNA screening for medical purposes, genetic testing for medical purposes; none of the foregoing services are used for medical coding and billing purposes
Owner
Board proceedings on this mark
- Opposition No. 91308617 — American Medical Association v. CPTx GmbH, filed 06 Jul 2026 (Terminated)
- Extension of Time to Oppose No. 98714397 — American Medical Association v. CPTx GmbH, filed 04 Feb 2026 (Terminated)
Prosecution history
- 01 Sept 2026 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 20 Jul 2026 — TTAB RELEASE CASE TO TRADEMARKS
- 20 Jul 2026 — OPPOSITION TERMINATED NO. 999999
- 20 Jul 2026 — OPPOSITION DISMISSED NO. 999999
- 06 Jul 2026 — EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
- 06 Jul 2026 — OPPOSITION INSTITUTED NO. 999999
- 04 Feb 2026 — EXTENSION OF TIME TO OPPOSE RECEIVED
- 06 Jan 2026 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 06 Jan 2026 — PUBLISHED FOR OPPOSITION
- 31 Dec 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 08 Dec 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 04 Nov 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 04 Nov 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 04 Nov 2025 — TEAS REQUEST FOR RECONSIDERATION RECEIVED
- 09 Oct 2025 — NOTIFICATION OF FINAL REFUSAL EMAILED